Fibronectin Predicts Seroclearance in Chronic Hepatitis B
Fibronectin may be a potential marker for hepatitis B surface antigen seroclearance.
Hepatitis B
HIV-Related Factors Predict Reinforced Hepatitis B Vaccination Success
Certain characteristics and HIV-related factors may help predict whether certain demographics of people with HIV will have an optimal response to reinforced hepatitis B virus vaccination.
Age, Race, and Genotype Associated With Hepatitis B Envelope Antigen Prevalence
Hepatitis B e antigen prevalence and other hepatitis B virus markers decline with age and differ by race with HBeAg persisting longer among Asian people.
No Significant Effect on Maternal/Fetal Bone Mineral Density With Maternal TDF Use
There was no significant effect of maternal tenofovir use for the prevention of mother-to-child transmission of HBV on bone mineral density in either the mother or child 1 year after delivery.
Antiviral Therapy May Prevent Liver Injury in Hepatitis B/TB Co-Infection
Patients with TB and HBV co-infection should be given antiviral treatment for HBV when anti-TB therapy is initiated.
Laboratory Abnormalities Common in Chronic Hepatitis B After Nucleotide Analog Discontinuation
Study findings showed that within 24 weeks of stopping 8 years or more of nucleotide analog therapy for chronic hepatitis B, nearly a third of patients experienced a grade 3 or higher laboratory abnormality.
NFID Initiative Working to Up Hepatitis B Vaccination Rates
A new initiative to increase hepatitis B virus vaccination rates among at-risk adults has been developed.
Novel Hepatitis B Virus Treatment Gets FDA’s Fast Track Designation
The FDA has granted Fast Track designation to a novel antiviral in development for the treatment of HBV infection.
Long-Term Safety Data for Tenofovir Alafenamide in Chronic Hepatitis B Added to Labeling
Vemlidy, a nucleoside analogue (reverse transcriptase inhibitor), is currently approved to treat chronic hepatitis B virus (HBV) infection in adults with compensated liver disease.
Hepatitis B Vaccines Compared in Older Adults With Type 2 Diabetes
For the analysis, study authors looked at data specifically for patients with type 2 diabetes aged 60 to 70 years.
Next post in Hepatitis
